Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? (Q39901701)

15 September 2017

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? (English)

1 reference

15 September 2017

1 reference

A El-Jawahri

1

1 reference

15 September 2017

H T Kim

2

1 reference

15 September 2017

D P Steensma

3

1 reference

15 September 2017

A M Cronin

4

1 reference

15 September 2017

R M Stone

5

1 reference

15 September 2017

C D Watts

6

1 reference

15 September 2017

Y-B Chen

7

1 reference

15 September 2017

C S Cutler

8

1 reference

15 September 2017

R J Soiffer

9

1 reference

15 September 2017

G A Abel

10

1 reference

15 September 2017

language of work or name

English

0 references

publication date

21 March 2016

1 reference

Bone Marrow Transplantation

15 September 2017

1 reference

15 September 2017

51

1 reference

15 September 2017

8

1 reference

15 September 2017

1121-1126

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2016.40

15 September 2017

0 references

cites work

The myelodysplastic syndromes: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Transplant strategies for patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

A Proportional Hazards Model for the Subdistribution of a Competing Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Acute myeloid leukemia and myelodysplastic syndromes in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.40

Costs and quality of life in patients with myelodysplastic syndromes

21 January 2018

1 reference

12 December 2020

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

12 December 2020

Symptom burden in hematologic malignancies

1 reference

12 December 2020

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

1 reference

12 December 2020

Quality of life and physicians' perception in myelodysplastic syndromes

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

12 December 2020

Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS).

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2016.40

1 reference

15 September 2017

1 reference